PolyPeptide Group targets €1.5bn valuation

By Aidan Gregory
12 Apr 2021

Swiss pharmaceutical ingredients manufacturing company PolyPeptide Group has filed for an IPO on the SIX Swiss Exchange, which is expected to value the company at around €1.5bn equivalent to €1.7bn equivalent, according to a source close to the deal.

The IPO is likely to be one of the largest in Switzerland this year. It will consist of new and existing shares, to give PolyPeptide Group a freefloat of at least 40% upon admission. 

PolyPeptide is a contract development and manufacturing organisation (CDMO) that makes peptides which go into drugs,” ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial